Xsensio
Private Company
Funding information not available
Overview
Xsensio is developing a novel wearable biosensor platform, Lab-on-Skin™, which leverages semiconductor-based technology to enable continuous, real-time monitoring of biochemical biomarkers like inflammation directly from the skin. Founded in 2014 as a spin-off from EPFL's Nanolab, the company aims to transform patient monitoring by providing actionable data for earlier intervention, moving from ICU settings to outpatient and home care. Backed by strong IP, a recent $7M Series A round, and collaborations with industry leaders like Texas Instruments, Xsensio is positioned to address significant unmet needs in proactive healthcare.
Technology Platform
Lab-on-Skin™: A miniaturized, semiconductor-based wearable sensing chip for continuous, real-time monitoring of biochemical biomarkers (e.g., inflammation markers) from skin surface fluids.
Opportunities
Risk Factors
Competitive Landscape
Xsensio competes in the emerging space of continuous biomarker monitoring. Direct competitors may include companies developing sweat-sensing patches (e.g., for electrolytes or cortisol), but Xsensio's focus on inflammation and clinical-grade, semiconductor-based sensing is distinctive. It faces potential competition from large medtech and consumer electronics companies investing in digital health, but its deep academic IP and focused clinical approach provide a defensible niche.